Quarterly ResultMay 4, 2026, 04:13 PM
Nuvation Bio Q1 Net Income $5.4M; Revenue $83.2M
AI Summary
Nuvation Bio reported a significant financial turnaround in Q1 2026, achieving a net income of $5.4 million compared to a net loss of $53.2 million in the same period last year. Total revenue dramatically increased to $83.2 million, up from $3.1 million year-over-year, driven by both new product revenue and substantial growth in collaboration and license agreements. The company also generated positive cash flow from operating activities, totaling $5.1 million.
Key Highlights
- Q1 2026 net income was $5.4 million, a significant improvement from a $53.2 million net loss in Q1 2025.
- Total revenue surged to $83.2 million in Q1 2026, up from $3.1 million in Q1 2025.
- Product revenue, net, reached $18.5 million in Q1 2026, compared to zero in the prior year.
- Collaboration and license agreements revenue increased to $64.7 million from $3.1 million year-over-year.
- Net cash provided by operating activities was $5.1 million, reversing a $42.6 million use in Q1 2025.
- Cash, cash equivalents, and marketable securities totaled $533.7 million as of March 31, 2026.
- Research and development expenses rose to $35.0 million from $24.6 million year-over-year.